.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Breast cancer continues to be a major global health concern, specifically the HER2-positive (HER2+) subtype. While targeted therapies have improved outcomes, S100-A11 anti-HER2 resistance remains a significant barrier to achieving a pathological complete response in many patients. A recent study has highlighted how the tumor microenvironment, specifically cancer-associated fibroblasts (CAFs), actively contributes to this therapy failure through paracrine signaling.
Researchers focused on the protein S100-A11, which CAFs secrete in response to anti-HER2 treatments like trastuzumab, pertuzumab, and docetaxel (TPD). The presence of extracellular S100-A11 significantly reduces the sensitivity of tumor cells to these drugs. This process suggests that the stroma is not just a passive background but an active participant in therapeutic resistance.
The mechanism behind this resistance involves the activation of the RAGE/STAT3 signaling pathway. When CAFs release S100-A11, it binds to the Receptor for Advanced Glycation End-products (RAGE) on tumor cells. This interaction leads to increased STAT3 phosphorylation, which promotes cell survival and proliferation. Consequently, the tumor cells can bypass the inhibitory effects of HER2-targeted agents.
Fortunately, pharmacological intervention appears possible. In laboratory and xenograft models, researchers used azeliragon, a RAGE antagonist, to block this interaction. This treatment successfully attenuated the effects of S100-A11 and restored sensitivity to TPD therapy. In addition, the study found that high levels of stromal S100-A11 in patient biopsies were linked to residual disease after surgery, making it a potential biomarker for treatment response.
These findings provide a clear rationale for targeting the stroma in HER2+ breast cancer. By inhibiting the S100-A11/RAGE/STAT3 axis, clinicians may be able to overcome adaptive resistance. However, further clinical validation is necessary to confirm these results in diverse patient populations. Future strategies might combine anti-HER2 drugs with RAGE inhibitors to improve long-term survival rates.
S100-A11 is secreted by cancer-associated fibroblasts and activates the RAGE/STAT3 signaling axis in breast cancer cells. This activation promotes tumor cell proliferation and survival, making standard anti-HER2 therapies less effective.
Azeliragon is a pharmacological antagonist of the RAGE receptor. It prevents the binding of S100-A11 to RAGE, thereby blocking the downstream signaling that causes therapy resistance in HER2-positive breast cancer.
Yes, the study suggests that high stromal expression of S100-A11 is associated with residual disease after neoadjuvant therapy. Therefore, it may help identify patients who are likely to experience resistance to standard treatments.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Luque M et al. Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. Neoplasia. 2026 May 19. doi: undefined. PMID: 42155177.
Hudson B et al. RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. npj Breast Cancer. 2023 Jul 13;9(1):59. doi: 10.1038/s41523-023-00564-9.
Ghanta P et al. Targeting S100A7/RAGE-driven Stat3/Serpin-E1 signaling for immunotherapy in metastatic breast cancer. ResearchGate. 2026 Apr 25. Abstract 7463.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study identifies S100-A11 as a CAF-derived protein that confers resistance to anti-HER2 therapies in breast cancer by activating the RAGE/STAT3 axis....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
